These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 31475808)

  • 1. The pharmacodynamic bases of the prescription of antimicrobials.
    Azanza Perea JR
    Rev Esp Quimioter; 2019 Sep; 32 Suppl 2(Suppl 2):35-37. PubMed ID: 31475808
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The pharmacokinetic-pharmacodynamic approach to a rational dosage regimen for antibiotics.
    Toutain PL; del Castillo JR; Bousquet-Mélou A
    Res Vet Sci; 2002 Oct; 73(2):105-14. PubMed ID: 12204627
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A proposal of a pharmacokinetic/pharmacodynamic (PK/PD) index map for selecting an optimal PK/PD index from conventional indices (AUC/MIC, Cmax/MIC, and TAM) for antibiotics.
    Kitamura Y; Yoshida K; Kusama M; Sugiyama Y
    Drug Metab Pharmacokinet; 2014; 29(6):455-62. PubMed ID: 25008846
    [TBL] [Abstract][Full Text] [Related]  

  • 4. How predictive is PK/PD for antibacterial agents?
    Frimodt-Møller N
    Int J Antimicrob Agents; 2002 Apr; 19(4):333-9. PubMed ID: 11978504
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Challenges in assessing microbial susceptibility and predicting clinical response to newer-generation fluoroquinolones.
    Segreti J; Jones RN; Bertino JS
    J Ocul Pharmacol Ther; 2012 Feb; 28(1):3-11. PubMed ID: 21999341
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Optimizing outcomes with antimicrobial therapy through pharmacodynamic profiling.
    Nicolau DP
    J Infect Chemother; 2003 Dec; 9(4):292-6. PubMed ID: 14691648
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluating amikacin dosage regimens in intensive care unit patients: a pharmacokinetic/pharmacodynamic analysis using Monte Carlo simulation.
    Zazo H; Martín-Suárez A; Lanao JM
    Int J Antimicrob Agents; 2013 Aug; 42(2):155-60. PubMed ID: 23756322
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The importance of pharmacokinetic/pharmacodynamic surrogate markers to outcome. Focus on antibacterial agents.
    Hyatt JM; McKinnon PS; Zimmer GS; Schentag JJ
    Clin Pharmacokinet; 1995 Feb; 28(2):143-60. PubMed ID: 7736689
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reappraisal of Contemporary Pharmacokinetic and Pharmacodynamic Principles for Informing Aminoglycoside Dosing.
    Bland CM; Pai MP; Lodise TP
    Pharmacotherapy; 2018 Dec; 38(12):1229-1238. PubMed ID: 30403305
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New concept and a theoretical consideration of the mechanism-based pharmacokinetics/ pharmacodynamics (PK/PD) modeling for antimicrobial agents.
    Sato N; Suzuki H; Hayashi H; Shibasaki S; Sugano T; Maebashi K; Kurosawa T; Shiomi M; Ogata H
    Jpn J Antibiot; 2008 Oct; 61(5):314-38. PubMed ID: 19260351
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacological indices in antibiotic therapy.
    Barger A; Fuhst C; Wiedemann B
    J Antimicrob Chemother; 2003 Dec; 52(6):893-8. PubMed ID: 14613960
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetic-pharmacodynamic modeling and simulation for in vivo bactericidal effect in murine infection model.
    Katsube T; Yamano Y; Yano Y
    J Pharm Sci; 2008 Apr; 97(4):1606-14. PubMed ID: 17705288
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rational dosing of antibiotics: the use of plasma concentrations versus tissue concentrations.
    Liu P; Müller M; Derendorf H
    Int J Antimicrob Agents; 2002 Apr; 19(4):285-90. PubMed ID: 11978499
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In Vitro Anaerobic Pharmacokinetic/Pharmacodynamic Model to Simulate the Bactericidal Activity of Levornidazole Against Bacteroides fragilis.
    Hu J; Zhang J; Chen Y; Liang W; Wu S
    Clin Ther; 2017 Apr; 39(4):828-836. PubMed ID: 28363695
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro Dynamic Pharmacokinetic/Pharmacodynamic (PK/PD) study and COPD of Marbofloxacin against Haemophilus parasuis.
    Sun J; Xiao X; Huang RJ; Yang T; Chen Y; Fang X; Huang T; Zhou YF; Liu YH
    BMC Vet Res; 2015 Dec; 11():293. PubMed ID: 26626889
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antibiotic pharmacokinetic and pharmacodynamic parameters in pediatric clinical practice.
    Cohen R; Grimprel E
    Arch Pediatr; 2017 Dec; 24(12S):S6-S8. PubMed ID: 29290237
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clarithromycin: pharmacokinetic and pharmacodynamic interrelationships and dosage regimen.
    Periti P; Mazzei T
    J Chemother; 1999 Feb; 11(1):11-27. PubMed ID: 10078776
    [TBL] [Abstract][Full Text] [Related]  

  • 18. What do we really know about antibiotic pharmacodynamics?
    Gunderson BW; Ross GH; Ibrahim KH; Rotschafer JC
    Pharmacotherapy; 2001 Nov; 21(11 Pt 2):302S-318S. PubMed ID: 11714222
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dose findings of antofloxacin hydrochloride for treating bacterial infections in an early clinical trial using PK-PD parameters in healthy volunteers.
    Li YF; Wang K; Yin F; He YC; Huang JH; Zheng QS
    Acta Pharmacol Sin; 2012 Nov; 33(11):1424-30. PubMed ID: 22864303
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The post-antibiotic sub-MIC effect in vitro and in vivo.
    Cars O; Odenholt-Tornqvist I
    J Antimicrob Chemother; 1993 May; 31 Suppl D():159-66. PubMed ID: 8335517
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.